European journal of cancer

Journal

Publication Venue For

  • Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).  153:223-233. 2021
  • A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.  137:1-9. 2020
  • Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.  135:211-220. 2020
  • Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.  101:95-104. 2018
  • Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.  64:1-11. 2016
  • Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review.  57:58-67. 2016
  • The KISS1 metastasis suppressor: A good night kiss for disseminated cancer cells.  46:1283-1289. 2010
  • Stat3 activation is required for the growth of U87 cell-derived tumours in mice.  45:677-684. 2009
  • Placenta growth factor is over-expressed and has prognostic value in human breast cancer.  41:2819-2827. 2005
  • HRT and breast cancer: Impact on population risk and incidence.  41:1775-1781. 2005
  • Long-term survival of women with breast cancer in New South Wales.  39:215-222. 2003
  • High expression of DNA topoisomerase IIα and Ki-67 antigen is associated with prolonged survival in glioblastoma patients.  38:1343-1347. 2002
  • DNA topoisomerase IIα expression in optic pathway gliomas of childhood.  38:393-400. 2002
  • Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) trial.  28:1833-1837. 1992
  • Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy combinations..  Suppl 1:141-146. 1980
  • International Standard Serial Number (issn)

  • 0014-2964
  • 0959-8049
  • Electronic International Standard Serial Number (eissn)

  • 1879-0852